sensilon 150 mikrogramm/20 mikrogramm tabletta
teva gyógyszergyár zrt. - desogestrel; ethinylestradiol -
sensilon 150 mikrogramm/30 mikrogramm tabletta
teva gyógyszergyár zrt. - desogestrel; ethinylestradiol -
sensitive spray evo
nextmune italy s.r.l. - newcastle disease virus, strain la sota, inactivated - külsoleges oldatos spray - newcastle disease virus/paramyxovirus vaccine - kutya, macska
sensitive shampoo evo
nextmune italy s.r.l. - eggdrop syndrome-1976 virus, strain b8/78, inactivated - sampon - avian adenovirus vaccine - kutya, macska
sensitive skin szappan
natural dog company - szappan - kutya
gentle shampoo for puppies and sensitive skins
g.r. kereskedelmi és szolgáltató bt. - turkey rhinotracheitis virus, strain clone k, live - sampon - turkey rhinotracheitis virus vaccine - kutya, macska
biodog ear & skin fold cleaner for sensitive dogs
sheila natúrkozmetikum gyártó és forgalmazó kft. - fülmosó oldat - kutya
sensitive skin family shampoo
g.r. kereskedelmi és szolgáltató bt. - sampon - ló, kedvtelésbol tartott nyúl, kutya, macska
fluenz tetra
astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, emberi - influenza vakcina, influenza, élő, attenuált - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. a fluenz tetra használatának hivatalos ajánlásokon kell alapulnia.
lynparza
astrazeneca ab - olaparib - petefészekrákos daganatok - daganatellenes szerek - petefészek cancerlynparza az monoterápiában a:fenntartó kezelésére felnőtt betegek speciális (figo stádium iii-iv) brca1/2-mutáns (germline és/vagy szomatikus) magas minőségű epithelialis petefészek, petevezeték cső vagy elsődleges peritoneális rák, akik a válasz (teljes vagy részleges) elvégzését követő első-sorban a platina-alapú kemoterápiához. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 és 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. a betegek korábban már kezelt antraciklin egy taxane a (neo)adjuváns vagy áttétes beállítás, kivéve, ha a betegek nem voltak alkalmasak ezek a kezelések (lásd 5. betegek hormon receptor (hr)-pozitív emlőrák is előrehaladtak-jén vagy azt követően előzetes endokrin terápia, vagy tekinteni alkalmatlan az endokrin terápia. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.